Skip to content

A Randomized Comparison of Transcervical Foley Bulb With Vaginal Misoprostol to Vaginal Misoprostol Alone for Induction of Labor

A Randomized Comparison of Transcervical Foley Bulb With Vaginal Misoprostol to Vaginal Misoprostol Alone for Induction of Labor

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02566005
Enrollment
200
Registered
2015-10-01
Start date
2015-09-30
Completion date
2016-07-31
Last updated
2018-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy

Keywords

Misoprostol, Induction, Foley

Brief summary

A randomized, prospective trial will be offered to women admitted to the Roosevelt Hospital labor floor for labor induction. The hypothesis is that the simultaneous use of a foley bulb together with vaginal misoprostol will result in shorter induction to delivery time compared with vaginal misoprostol alone

Detailed description

1. Objectives The hypothesis is that cervical ripening using a foley bulb together with vaginal misoprostol (cytotec) will result in shorter induction to delivery time compared with vaginal misoprostol alone 2. Background The rate of induction of labor in the United States is approximately 20% of all births. Induction of labor can result in prolonged labor and increases the rate of cesarean delivery, both of which are associated with increased maternal and neonatal morbidity. Ripening of an unfavorable cervix has become an integral part of the labor induction process. The best method of cervical ripening remains controversial; no one method has proved to be superior. Women requiring labor induction often present with unfavorable cervices which can lead to a prolonged induction. Cervical ripening is often done to increase the likelihood of successful labor induction. Misoprostol (cytotec) is PGE1 analog and widely used for cervical ripening and is the preferred method of induction of labor based on the safety reported literature. Low-dose (25 mcg) intravaginal misoprostol appears to be safe and effective for cervical ripening in term pregnancy for patients without a history of cesarean section. Compared with other cervical ripening methods, misoprostol has an increased rate of vaginal delivery within 24 hours without significant differences in cesarean section rates or fetal outcomes. The use of the foley catheter for induction of labor was first described by Krause in 1953. In 1967 Embrey and Mollison reported a 94% successful induction rate after using the foley catheter for cervical ripening. Since then, several studies found transcervical foley catheters as effective as prostaglandins preparations for ripening without an increased risk of uterine rupture. There are many proposed methods for induction of labor including mechanical (transcervical foley bulb) and chemical methods (prostaglandins, oxytocin). A number of randomized trials have compared the use of foley bulb, oxytocin and misoprostol in different combinations for induction of labor and their results are contradictory with regards to induction to delivery time, successful vaginal delivery and labor complications. There are two studies that evaluated the foley bulb with misoprostol comparing to misoprostol alone. Carbone el al study, found the mean induction to delivery time was 3 hours shorter with the combination of the foley bulb and vaginal misoprostol when compared to vaginal misoprostol alone. In a study by Chung et al, there was no difference in the induction to delivery time. Therefore given the contradicting results regarding induction of labor using foley bulb with misoprostol or misoprostol alone, the purpose of our study is to determine if there is a decrease in the induction to delivery time with one method versus the other. 3. Setting of the Human Research Research will take place on the labor and delivery floor of Roosevelt Hospital 4. Study Design a) Recruitment Methods Women admitted to labor and delivery at Roosevelt Hospital will be asked to participate in the study if they are to have an induction of labor at or beyond term (37weeks of gestation). Patients will be screened and those meeting the eligibility criteria will be approached. Informed consent will be obtained. After a discussion about the study with an eligible interested subject, an investigator will review the consent with them. The investigator will give the potential subject the opportunity to ask any questions and have them answered. Potential participants will be given the opportunity to think about the study. (Only those investigators listed as study personnel and authorized to obtain consent, will obtain informed consent). Once a patient wishes to join the study and informed consent is obtained, the subject can participate. Each subject will receive a signed copy of the consent form. The subject can withdraw from the study at any time without any retribution.

Interventions

DEVICEmisoprostol

25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist).

a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours.

Sponsors

St. Luke's-Roosevelt Hospital Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Term 37 weeks or more, singleton in cephalic presentation * Age 18 years and older * Patient admitted for induction of labor

Exclusion criteria

* Malpresentation * Preterm labor less than 37 weeks of gestation * Patients with fetal anomalies * Premature rupture of membranes * If the cervix is closed and unable to place the foley bulb * Multiple gestation * Non-reassuring fetal heart tracing * Contraindication to misoprostol * Contraindication to vaginal delivery (i.e. placenta previa, vasa previa, active vaginal bleeding, marginal previa, macrosomia, etc). History of prior uterine surgery such as cesarean section or myomectomy

Design outcomes

Primary

MeasureTime frameDescription
Per Treatment Protocol: Time (Hours) From Induction to Deliveryday 1
The Time Interval From Induction to Delivery: All ParticipantsDay 1During labor from the start of the induction to the delivery
Time (Hours) From Induction to Delivery: NulliparousDay 1
Time (Hours) From Induction to Delivery: MultiparousDay 1
Time From Induction to Delivery: VDDay 1Time (hours) from induction to delivery: Vaginal Delivery (VD)
Time From Induction to Delivery: CDDay 1Time (hours) from induction to delivery: Cesarean Delivery (CD)

Secondary

MeasureTime frame
The Time From Induction Until to Active Phase LaborDay 1
The Time From Active Phase to DeliveryDay 1
Incidence of ChorioamnionitisDay 1
Incidence of Uterine TachysystoleDay 1
Incidence of Patient DiscomfortDay 1
Estimated Blood LossDay 1

Countries

United States

Participant flow

Recruitment details

During the study period from September 2015-July 2016, 4767 patients delivered at Mount Sinai West and of these, 1423 deliveries followed induction of labor. A total of 200 patients consented to participate in the study and were randomized, 100 to each group.

Participants by arm

ArmCount
Misoprostol Group
25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist.)
100
Misoprostol and Foley Bulb Group
25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. In addition, a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours. Oxytocin will be initiated in those patients who were not in labor after expulsion or removal of the catheter.
100
Total200

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall Studydid not receive foley01
Overall Studylabor after randomization04
Overall Studyreceived foley80
Overall Studyvaginal bleeding01

Baseline characteristics

CharacteristicMisoprostol GroupMisoprostol and Foley Bulb GroupTotal
Age, Continuous31.5 years
STANDARD_DEVIATION 5.9
31.8 years
STANDARD_DEVIATION 6.3
31.6 years
STANDARD_DEVIATION 6.1
Anesthesia
General Anesthesia
0 Participants3 Participants3 Participants
Anesthesia
Neuraxial anesthesia
96 Participants91 Participants187 Participants
Anesthesia
None
4 Participants6 Participants10 Participants
Bishop score at misoprostol placement2.71 units on a scale
STANDARD_DEVIATION 1.78
3.17 units on a scale
STANDARD_DEVIATION 1.94
2.9 units on a scale
STANDARD_DEVIATION 1.8
BMI31.8 kg/m^2
STANDARD_DEVIATION 6.8
31.22 kg/m^2
STANDARD_DEVIATION 5.7
31.56 kg/m^2
STANDARD_DEVIATION 6.3
Gestational age at delivery39.4 weeks
STANDARD_DEVIATION 1.4
39.6 weeks
STANDARD_DEVIATION 1.3
39.4 weeks
STANDARD_DEVIATION 1.4
Indication for induction
Advanced maternal age
1 Participants4 Participants5 Participants
Indication for induction
Gestational diabetes/Diabetes
11 Participants11 Participants22 Participants
Indication for induction
Hypertensive disorder
28 Participants20 Participants48 Participants
Indication for induction
Oligohydramnios/Polyhydramnios
21 Participants22 Participants43 Participants
Indication for induction
Others
18 Participants22 Participants40 Participants
Indication for induction
Post-EDC
21 Participants21 Participants42 Participants
Indications for cesarean delivery
Arrest of descent
5 Participants4 Participants9 Participants
Indications for cesarean delivery
Arrest of dilation
9 Participants6 Participants15 Participants
Indications for cesarean delivery
Failed induction of labor
3 Participants1 Participants4 Participants
Indications for cesarean delivery
Non-reassuring Fetal tracing
20 Participants19 Participants39 Participants
Indications for cesarean delivery
Others
1 Participants0 Participants1 Participants
Insurance
Private
59 Participants53 Participants112 Participants
Insurance
Service
41 Participants47 Participants88 Participants
Mode of delivery
Cesarean Delivery
38 Participants30 Participants68 Participants
Mode of delivery
Forceps Vaginal Delivery
2 Participants1 Participants3 Participants
Mode of delivery
Spontaneous Vaginal Delivery
48 Participants59 Participants107 Participants
Mode of delivery
Vacuum Vaginal Delivery
12 Participants10 Participants22 Participants
Parity
Multiparous
26 Participants30 Participants56 Participants
Parity
Nulliparous
74 Participants70 Participants144 Participants
Sex: Female, Male
Female
100 Participants100 Participants200 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 1000 / 100
other
Total, other adverse events
0 / 1000 / 100
serious
Total, serious adverse events
0 / 1000 / 100

Outcome results

Primary

Per Treatment Protocol: Time (Hours) From Induction to Delivery

Time frame: day 1

Population: those participants on treatment protocol

ArmMeasureValue (MEAN)Dispersion
Misoprostol GroupPer Treatment Protocol: Time (Hours) From Induction to Delivery20.5109 hoursStandard Deviation 10.09
Misoprostol and Foley Bulb GroupPer Treatment Protocol: Time (Hours) From Induction to Delivery16.6814 hoursStandard Deviation 7.47
Primary

The Time Interval From Induction to Delivery: All Participants

During labor from the start of the induction to the delivery

Time frame: Day 1

ArmMeasureValue (MEAN)Dispersion
Misoprostol GroupThe Time Interval From Induction to Delivery: All Participants20.97 hoursStandard Deviation 10.27
Misoprostol and Foley Bulb GroupThe Time Interval From Induction to Delivery: All Participants16.27 hoursStandard Deviation 7.6
Primary

Time From Induction to Delivery: CD

Time (hours) from induction to delivery: Cesarean Delivery (CD)

Time frame: Day 1

ArmMeasureValue (MEAN)Dispersion
Misoprostol GroupTime From Induction to Delivery: CD24.38 hoursStandard Deviation 12.49
Misoprostol and Foley Bulb GroupTime From Induction to Delivery: CD17.95 hoursStandard Deviation 9.29
Primary

Time From Induction to Delivery: VD

Time (hours) from induction to delivery: Vaginal Delivery (VD)

Time frame: Day 1

ArmMeasureValue (MEAN)Dispersion
Misoprostol GroupTime From Induction to Delivery: VD18.87 hoursStandard Deviation 8
Misoprostol and Foley Bulb GroupTime From Induction to Delivery: VD15.55 hoursStandard Deviation 6.7
Primary

Time (Hours) From Induction to Delivery: Multiparous

Time frame: Day 1

Population: for nulliparous participants

ArmMeasureValue (MEAN)Dispersion
Misoprostol GroupTime (Hours) From Induction to Delivery: Multiparous15.99 hoursStandard Deviation 7.4
Misoprostol and Foley Bulb GroupTime (Hours) From Induction to Delivery: Multiparous11.89 hoursStandard Deviation 4.6
Primary

Time (Hours) From Induction to Delivery: Nulliparous

Time frame: Day 1

Population: for nulliparous participants

ArmMeasureValue (MEAN)Dispersion
Misoprostol GroupTime (Hours) From Induction to Delivery: Nulliparous22.7 hoursStandard Deviation 10.58
Misoprostol and Foley Bulb GroupTime (Hours) From Induction to Delivery: Nulliparous18.15 hoursStandard Deviation 7.87
Secondary

Estimated Blood Loss

Time frame: Day 1

ArmMeasureValue (MEAN)Dispersion
Misoprostol GroupEstimated Blood Loss493.3 mlStandard Deviation 274
Misoprostol and Foley Bulb GroupEstimated Blood Loss490.5 mlStandard Deviation 304.1
Secondary

Incidence of Chorioamnionitis

Time frame: Day 1

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Misoprostol GroupIncidence of Chorioamnionitis8 Participants
Misoprostol and Foley Bulb GroupIncidence of Chorioamnionitis4 Participants
Secondary

Incidence of Patient Discomfort

Time frame: Day 1

Population: data not collected

Secondary

Incidence of Uterine Tachysystole

Time frame: Day 1

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Misoprostol GroupIncidence of Uterine Tachysystole12 Participants
Misoprostol and Foley Bulb GroupIncidence of Uterine Tachysystole6 Participants
Secondary

The Time From Active Phase to Delivery

Time frame: Day 1

ArmMeasureValue (MEAN)Dispersion
Misoprostol GroupThe Time From Active Phase to Delivery3.11 hoursStandard Deviation 2.75
Misoprostol and Foley Bulb GroupThe Time From Active Phase to Delivery3.76 hoursStandard Deviation 3
Secondary

The Time From Induction Until to Active Phase Labor

Time frame: Day 1

ArmMeasureValue (MEAN)Dispersion
Misoprostol GroupThe Time From Induction Until to Active Phase Labor17.43 hoursStandard Deviation 8.6
Misoprostol and Foley Bulb GroupThe Time From Induction Until to Active Phase Labor12.81 hoursStandard Deviation 5.83

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026